BMO Capital Reiterates Outperform Rating on Legend Biotech Corp. (LEGN)

BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $90.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).

The analyst commented, "Updated Cartitude-4 34mo data demonstrate that Carvykti continues to provide a statistically significant OS benefit (>76%) vs. SoC (64%) at 30mo, further establishing Carvykti's strong/durable/ safe profile as a 2L+ MM treatment. Recent competitor setbacks, here, in combination with Carvykti's differentiating profile (including 7-day CRS onset that best suits Carvykti for outpatient dosing), render Carvykti the leading CAR-T therapy in MM that could ultimately generate up to ~$10B in peak sales (similar to Darzalex).
We don't anticipate anito-cel readout (4Q24) to significantly impact Carvykti's outlook given
Carvykti's robust positioning. Remaining OP."

For an analyst ratings summary and ratings history on Legend Biotech Corp. click here. For more ratings news on Legend Biotech Corp. click here.

Shares of Legend Biotech Corp. closed at $49.27 yesterday.

You May Also Be Interested In

• Oppenheimer Downgrades Legend Biotech Corp. (LEGN) to Perform, 'CEO/Partnership/Competition Overhangs to Cap Upside'
• DeFi Technologies posts $7.8M revenue and $2.3M loss in Q2 2026
• BIO-key posts 13% revenue gain and narrower Q2 net loss